Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Savara to Present at Two Upcoming Healthcare Conferences


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences:

Guggenheim 6th Annual Biotechnology Conference
February 7, 2024 at 8:30am PT/ 11:30am ET
Fireside Chat
St. Regis Hotel, New York City, NY

Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 13, 2024 at 7:40am PT / 10:40am ET
Corporate Presentation
Virtual Conference

A webcast of each presentation will be available through the Investors page of Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for at least 30 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).


These press releases may also interest you

at 06:05
Urgent Cybersecurity Risks Identified in Paris 2024 Olympic Games Online Infrastructure by Outpost24
Outpost24, a leading provider of cyber threat exposure management solutions, has today released its research findings after investigating the online infrastructure of the upcoming 2024 Paris Olympic Games. The research revealed that while, overall,...

at 06:05
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2024. Amounts are expressed in U.S. dollars. Total net revenue was $50.3 million for the three months ended March 31,...

at 06:05
LayerX Security Raises $26M for its Browser Security Platform, Enabling Employees to Work Securely from Any Browser, Anywhere
LayerX, pioneer of the LayerX Browser Security platform, today announced $26 million in Series A funding led by Glilot+, the early-growth fund of Glilot Capital Partners, with participation from Dell Technologies Capital and other investors. Lior...

at 06:05
Florin Filote joins ThredUp as General Manager of Europe
ThredUp , one of the largest online resale platforms for apparel, shoes, and accessories, today announced the appointment of Florin Filote as the company's General Manager of Europe. With nearly two decades of experience in retail and ecommerce with...

at 06:01
Shutterstock Enters into Definitive Agreement to Acquire Envato, Featuring Envato Elements, the Unlimited Creative Content Subscription
Shutterstock, Inc. , a leading global creative platform offering high-quality creative content for transformative brands, digital media and marketing companies, today announced that it entered into a definitive agreement to acquire Envato Pty Ltd....

at 06:00
Potential secures additional $2M to drive AI-powered terrain perception technologies to market
The seed fund extension will underpin innovation programs with global automotive manufacturers as momentum builds toward production-scale deployment. $2M CAD seed round extensionRound includes returning partners Brightspark Ventures, Build Ventures...

More news about Science and technology...


News published on and distributed by: